These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 30087611)
1. Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug. Berger B; Bachmann F; Duthaler U; Krähenbühl S; Haschke M Front Pharmacol; 2018; 9():774. PubMed ID: 30087611 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail. Berger B; Donzelli M; Maseneni S; Boess F; Roth A; Krähenbühl S; Haschke M Front Pharmacol; 2016; 7():443. PubMed ID: 27917125 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119 [TBL] [Abstract][Full Text] [Related]
4. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. Venkatakrishnan K; von Moltke LL; Greenblatt DJ J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960 [TBL] [Abstract][Full Text] [Related]
5. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885 [TBL] [Abstract][Full Text] [Related]
6. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Barham HM; Lennard MS; Tucker GT Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638 [TBL] [Abstract][Full Text] [Related]
7. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Crewe HK; Ellis SW; Lennard MS; Tucker GT Biochem Pharmacol; 1997 Jan; 53(2):171-8. PubMed ID: 9037249 [TBL] [Abstract][Full Text] [Related]
8. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Kudo S; Odomi M Eur J Clin Pharmacol; 1998 May; 54(3):253-9. PubMed ID: 9681669 [TBL] [Abstract][Full Text] [Related]
9. Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study. Derungs A; Donzelli M; Berger B; Noppen C; Krähenbühl S; Haschke M Clin Pharmacokinet; 2016 Jan; 55(1):79-91. PubMed ID: 26123704 [TBL] [Abstract][Full Text] [Related]
10. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609 [TBL] [Abstract][Full Text] [Related]
11. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies. Hamaoka N; Oda Y; Hase I; Asada A Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629 [TBL] [Abstract][Full Text] [Related]
12. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Beulz-Riché D; Grudé P; Puozzo C; Sautel F; Filaquier C; Riché C; Ratanasavanh D Fundam Clin Pharmacol; 2005 Oct; 19(5):545-53. PubMed ID: 16176333 [TBL] [Abstract][Full Text] [Related]
13. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Dehal SS; Kupfer D Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005 [TBL] [Abstract][Full Text] [Related]
14. Regio- and Stereo-Selective Oxidation of a Cardiovascular Drug, Metoprolol, Mediated by Cytochrome P450 2D and 3A Enzymes in Marmoset Livers. Uehara S; Ishii S; Uno Y; Inoue T; Sasaki E; Yamazaki H Drug Metab Dispos; 2017 Aug; 45(8):896-899. PubMed ID: 28495902 [TBL] [Abstract][Full Text] [Related]
15. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974 [TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026 [TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes. Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220 [TBL] [Abstract][Full Text] [Related]
18. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo. Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337 [TBL] [Abstract][Full Text] [Related]
19. Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. Tang L; Ye L; Lv C; Zheng Z; Gong Y; Liu Z Toxicol Lett; 2011 Apr; 202(1):47-54. PubMed ID: 21277363 [TBL] [Abstract][Full Text] [Related]
20. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. Ellis SW; Rowland K; Ackland MJ; Rekka E; Simula AP; Lennard MS; Wolf CR; Tucker GT Biochem J; 1996 Jun; 316 ( Pt 2)(Pt 2):647-54. PubMed ID: 8687412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]